Last reviewed · How we verify

Neostigmine w/ Glycopyrrolate

University of Texas Southwestern Medical Center · FDA-approved active Small molecule

Neostigmine w/ Glycopyrrolate is a Acetylcholinesterase inhibitor with anticholinergic agent Small molecule drug developed by University of Texas Southwestern Medical Center. It is currently FDA-approved for Myasthenia gravis, Reversal of neuromuscular blockade.

Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate blocks muscarinic receptors to counteract cholinergic side effects.

Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate blocks muscarinic receptors to counteract cholinergic side effects. Used for Myasthenia gravis, Reversal of neuromuscular blockade.

At a glance

Generic nameNeostigmine w/ Glycopyrrolate
SponsorUniversity of Texas Southwestern Medical Center
Drug classAcetylcholinesterase inhibitor with anticholinergic agent
TargetAcetylcholinesterase (neostigmine); muscarinic acetylcholine receptors (glycopyrrolate)
ModalitySmall molecule
Therapeutic areaNeurology
PhaseFDA-approved

Mechanism of action

Neostigmine is a reversible acetylcholinesterase inhibitor that increases acetylcholine concentration at the neuromuscular junction and in the central and peripheral nervous systems. Glycopyrrolate is an anticholinergic agent added to this combination to prevent excessive muscarinic stimulation (salivation, bronchospasm, bradycardia) that would otherwise result from neostigmine monotherapy. Together, they enhance nicotinic effects while minimizing unwanted muscarinic effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Neostigmine w/ Glycopyrrolate

What is Neostigmine w/ Glycopyrrolate?

Neostigmine w/ Glycopyrrolate is a Acetylcholinesterase inhibitor with anticholinergic agent drug developed by University of Texas Southwestern Medical Center, indicated for Myasthenia gravis, Reversal of neuromuscular blockade.

How does Neostigmine w/ Glycopyrrolate work?

Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate blocks muscarinic receptors to counteract cholinergic side effects.

What is Neostigmine w/ Glycopyrrolate used for?

Neostigmine w/ Glycopyrrolate is indicated for Myasthenia gravis, Reversal of neuromuscular blockade.

Who makes Neostigmine w/ Glycopyrrolate?

Neostigmine w/ Glycopyrrolate is developed and marketed by University of Texas Southwestern Medical Center (see full University of Texas Southwestern Medical Center pipeline at /company/university-of-texas-southwestern-medical-center).

What drug class is Neostigmine w/ Glycopyrrolate in?

Neostigmine w/ Glycopyrrolate belongs to the Acetylcholinesterase inhibitor with anticholinergic agent class. See all Acetylcholinesterase inhibitor with anticholinergic agent drugs at /class/acetylcholinesterase-inhibitor-with-anticholinergic-agent.

What development phase is Neostigmine w/ Glycopyrrolate in?

Neostigmine w/ Glycopyrrolate is FDA-approved (marketed).

What are the side effects of Neostigmine w/ Glycopyrrolate?

Common side effects of Neostigmine w/ Glycopyrrolate include Salivation, Bronchospasm, Bradycardia, Muscle fasciculations, Nausea.

What does Neostigmine w/ Glycopyrrolate target?

Neostigmine w/ Glycopyrrolate targets Acetylcholinesterase (neostigmine); muscarinic acetylcholine receptors (glycopyrrolate) and is a Acetylcholinesterase inhibitor with anticholinergic agent.

Related